Eyenovia to present at upcoming h.c. wainwright 3rd annual ophthalmology virtual conference

New york, aug. 09, 2023 (globe newswire) -- eyenovia, inc. (nasdaq: eyen), an ophthalmic technology company commercializing mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis and developing the optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will deliver a presentation and participate in a panel discussion at the h.c. wainwright 3rd annual ophthalmology day, which is taking place virtually on august 16, 2023. presentation and panel details are below:
EYEN Ratings Summary
EYEN Quant Ranking